RT Journal Article
SR Electronic
T1 Effects of Metformin compared to Thiazolidinediones on vascular endothelial function in Polycystic Ovary syndrome: A systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.23.20018580
DO 10.1101/2020.01.23.20018580
A1 Mazumder, Hoimonty
A1 Faizah, Farah
A1 Hossain, Md. Mahbub
YR 2020
UL http://medrxiv.org/content/early/2020/01/27/2020.01.23.20018580.abstract
AB Metformin and Thiazolidinediones are insulin sensitizers used as the first-line treatment of PCOS, which are recently being examined for their extensive beneficial impacts at biochemical and molecular level of body function in Polycystic ovary syndrome. Therefore, purpose of this review is to compare the effectiveness of Metformin and Thiazolidinediones on vascular endothelial function in PCOS. MEDLINE (1966- October 2018), CINAHL (1982 to October 2018), Cochrane Central Register of Controlled Trials and Cochrane Menstrual Disorders and Subfertility Group trials register (October 2018) and Google Scholar were searched electronically without language restriction. Three Randomized controlled trials (RCTs) were selected with a total of 90 participants comparing effect of Metformin (Intervention) to Thiazolidinediones (Comparator) with an outcome on endothelial function among women with PCOS. In results, Meta-analysis shows no statistically significant difference on endothelial-dependent vasodilation between Metformin and Thiazolidinedione (p value= 0.59 at 95% CI - 1.31, 0.74).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received at any stage of preparing this manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSince this is a systematic review, hence data was collected from the primary studies included in this review as per predetermined eligibility criteria.